For the generation of the human skin-derived precursors (hSKP) spheroids, ultra-low attachment 96-well plates, cell-repellent (Greiner) are used. hSKP cultured on tissue culture plates are detached with trypple (5 minutes) and collected in a tube. After centrifugation, hSKP are counted at the Burker

Polycaprolactone (PCL) fiber materials are fabricated using an electrospinning method. Molecular weight of PCL is 45 000 Da (Sigma-Aldrich). The electrospinning process is performed using 18wt% PCL solution dissolved in chloroform:ethanol at a ratio of 9:1. Two high-voltage sources are used to

Drug-induced phospholipidosis (DIPL) is a metabolic disorder characterized by an excessive intracellular accumulation of phospholipids caused by cationic drugs. Hepatic cells derived from human skin are evaluated as an in vitro model to investigate DIPL and its mechanisms. Human skin stem cells

The effect of fluidics that mimic the blood flow in the liver sinusoids, is evaluated during the hepatic differentiation of human skin-derived precursors (hSKP). In a standard bi-dimensional (2D) cell culture system, hSKP are differentiated to hSKP-HPC for 24 days in static conditions. In a

Non-alcoholic fatty liver disease (NAFLD) ranges from simple steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause health complications. However, in 5-10% of the cases it proceeds to NASH in which hepatic inflammation occurs

This method describes a well-known optimised human in vitro model of drug-induced cholestasis. Cryopreserved primary human hepatocytes are cultured between two layers of extracellular matrix scaffold, which will delay dedifferentiation and allows to restore cell-extracellular matrix interactions.

Loss of acinar differentiation drives pancreatic cancer. An established human in vitro experimental model is used in our lab to study this process. Pancreatic exocrine cells from human donors are placed in suspension culture in Advanced RPMI medium supplemented with 5% heat-inactivated fetal bovine